Meet our leadership team
Alain Lamproye joined Yposkesi as CEO in January 2017. Previously, he served as President of the BioPharma Business Unit of Novasep from 2012 to 2017, as well as CEO of its subsidiary dedicated to gene therapy (Henogen, Belgium). Between 2003 and 2012 he held various managerial positions in pharmaceutical operations at Merck Serono, including serving as Site Director at Billerica (USA). He previously worked as GMP Production Director at Eurogentec (Belgium) for 14 years. Alain holds an M.S. in biology from the University of Liège (Belgium).
Armandine Bonnet joined Yposkesi as General Counsel in September 2018. Previously, she served for two years as Vice-President Legal Affairs of DBV Technologies, a Nasdaq and Euronext-listed biopharmaceutical company, where she built and led the worldwide legal and compliance functions of the company. Prior to that, she successively held the positions of General Counsel of the German generic producer Ratiopharm for over three years and of Pharnext, a French biotechnology company. From 1999 to 2006, Armandine Bonnet practiced as a corporate attorney at the international law firm Landwell (PwC). She was admitted to the Paris Bar in 1999 and received an LLM in international business law from King’s College London (UK).
Christophe Cambouris joined Yposkesi as Chief Commercial Officer in July 2022. With over 20 years of business experience in the cell and gene therapy field, Christophe has held several business development and marketing positions. These include 14 years at Miltenyi Biotec where he was Sales and Marketing Director then Europen Director for Strategic Accounts. Christophe holds an Immunology master’s degree from the Ecole Pratique des Hautes Etudes in Paris.
Olivier Courné joined Yposkesi as Technical Director in 2016. With over 17 years of experience in the pharmaceutical industry in the production of parenteral products, Olivier began his career in the automotive industry. For 9 years, he was the head of maintenance and HSE, for which he contributed to the construction and operation of a fuel tank production site. In 1999, Olivier joined an Organon production site where he structured maintenance activities and maintenance methods. In 2010, he joined an MSD site in animal health, to take over maintenance activities. Olivier holds a degree in Industrial Maintenance Management.
Philippe Cuif joined Yposkesi as Chief Information Officer in 2019. With 25 years of experience in IT management working with international groups, Philippe held various positions in IT management. Before joining Yposkesi, he was the European IT manager of Vetoquinol, a French veterinary pharmaceutical laboratory, where he managed the company’s global IT system. He began his career in networking and communication in the automotive industry where he successively held positions of Networks Architect and IT infrastructure manager, contributing to the merger and integration of several subsidiaries IT systems. He holds a degree in computer engineering and a degree in management of information systems.
Louis-Marie De Montgrand
Louis-Marie de Montgrand joined Yposkesi as Chief Operational Officer in June 2022. With more than 25 years of experience in leading Operations in Biopharma Industries, Louis-Marie held several positions at major industrial & CDMO actors. He started his carrier working for Sanofi as an EIT Process Eng, followed by 10 years at GSK being Head of Production then Head of Technical Services. After that, Louis-Marie became CMO Operations Director at Novasep and VP Operations – Viral Vector Services for Europe at Thermofisher.
Morad El Gueddari
Morad El Gueddari joined Yposkesi as Head of Operations in 2018 and became the Chief Pharmacist and Head of Quality in June 2022. Morad has 15 years of bioproduction and cell and gene therapy experience gained in various managerial roles in quality and GMP manufacturing at European pharmaceutical companies, including LFB and CELLforCURE (now part of Novartis). Dr. El Gueddari holds a PharmD from the Limoges, France Pharmacy School.
Patrick Lansky joined Yposkesi as VP of US Sales and Marketing in 2019. Patrick has worked in various positions in the life sciences for the past 25 years before joining Yposkesi. He started his career working at Idec Pharmaceuticals where he spent 5 years learning the ins and outs of protein development and manufacturing. Patrick then moved to the business side of the industry where he spent 8 years selling single-use systems for Stedim. He then spends 10 years developing business for a gene and cell therapy CMO. Patrick holds a BS in Physiology and Neuroscience from UC San Diego and currently resides in La Jolla, CA.
Erwan Martin joined Yposkesi as Secretary General in 2019. With over 20 years of experience in the biotechnology and medical technology industries, Erwan is an expert in finance and corporate development. After starting his career in an audit and consulting firm, he co-founded Cytomics Pharmaceuticals, a biotechnology company specialized in the discovery of new medicines, where he was a member of the Management Board and Chief Financial Officer. He supported the Company’s development, overseeing several financing rounds worth a total of more than €20 million. In 2009 Erwan became Chief Financial Officer of Genomic Vision (Euronext: GV) and VP Corporate Development until 2017, undertaking financing operations such as the Company’s initial public offering in 2014. Before joining Yposkesi he was the Group Chief Financial Officer of Cellnovo Group (Euronext: CLNV), a medical technology company in the diabetes space. Erwan Martin holds an MBA from Warwick Business School (UK) and is a graduate of the Ecole Supérieure de Commerce (ESC) of Toulouse.
Isabelle Moghimi-Colin joined Yposkesi as Human Resources Director in 2016. With 20 years of HR management experience, Isabel held various HR managerial positions in the service, oil, and pharmaceutical industries, within companies such as Motul and MSD France (Merck Group). Isabelle holds a Master’s degree in political science and business law from the University of Paris I & V and a Master’s degree in Human Resources from the Paris conservatory for continuing adult education (CNAM).
Olivier Maurion joined Yposkesi in 2018 to create and lead the Analytical Expertise Center. In 2022, he led Yposkesi’s industrial-scale readiness for commercial batch manufacturing Program and became Business Excellence Director in November 2022. With over 15 years of experience in Project Management, Manufacturing, and Development in Pharma and Biopharma Industries, for small & large molecules (sterile, combined, and plasma-derived medicinal products), Olivier held several positions at major industrial & CDMO actors such as Johnson & Johnson, Roche, LFB, and Cenexi. Olivier earned an MS in Chemical Engineering from ENSIC Nancy, institute for chemical and processing engineering, and holds a doctoral degree in Pharmacy from the University Pharmacy of Nancy (France). He is also an executive MBA graduate from the Paris Dauphine University (France) and from UQAM Montréal (Canada).
Brian Mullan joined Yposkesi as Chief Technical Officer in 2020. With over 20 years of experience working internationally (Europe, USA) with large multinational companies, Brian has held leadership roles in late-phase process development, product launch, and commercial supply for large pharmaceutical companies making therapeutic monoclonal antibodies (MAbs). He spent nine years at Novartis, where he held posts as head of manufacturing science and technology and as a global technical project leader. Between 2008 and 2012, he was process tech transfer lead at Eli Lilly. Prior to that, he worked at Janssen (Centocor) Biologics and Sanofi-Aventis (in the area of C> R&D). He holds a PhD in Viral Genetics from University College Cork, Ireland, and an MBA from the Open University Business School, UK.
Christel Rivière, PhD, joined Yposkesi as Director of CMC project management in 2016. With over 20 years of experience in the gene therapy field, she started her career at the Gene Therapy R&D organization Genethon, where she managed the process & analytical development of AAV and LV vectors. She also contributed to the implementation of CDMO activities within Genethon with external partners and clients. Christel holds a PhD in Oncology from the University of Paris XI.
Prof. José Alain Sahel
President Department of Ophthalmology – University of Pittsburgh
Prof. Ophthalmology – University Pierre-et-Marie-Curie Paris
Prof. Biomedical Siences – Institute of Ophthalmology, « University College Cumberlege », London
Prof. Alain Fischer
Director – Founder, Institute Imagine, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
Professor Collège de France
Member of the National Medicine Academy USA
Dr. Serge Braun
Scientific Director AFM-Telethon
Member of the French Pharmacy Academy